Alan Brooks, PhD
Alan oversees the company’s in vivo therapeutic gene editing programs.
Head of Preclinical
Prior to joining Metagenomi in November of 2019, Alan was Principal Scientist at Casebia Therapeutics where he initiated and led CRISPR/Cas9 genome editing projects for hematology. Prior to that, Alan led projects in gene therapy and protein therapeutics with a focus on Hemophilia and rare hematological disorders during his 10yrs at Bayer Healthcare. Before joining Bayer, Alan worked at several biotech startups with a focus on cardiovascular and neurological diseases.
Alan received his Bachelor of Science from the University of Leicester in the UK and went on to complete a Ph.D. in molecular biology at the University of Warwick before joining the Gladstone Institute of Cardiovascular Disease as a postdoctoral fellow. In his 30+ years in the pharma/biotech industry, Alan’s research has led to 20 publications, numerous patent filings and presentation of his work at major scientific meetings.